Basic information Safety Supplier Related

3,6-DICHLORO-BENZO[B]THIOPHENE-2-CARBOXYLIC ACID

Basic information Safety Supplier Related

3,6-DICHLORO-BENZO[B]THIOPHENE-2-CARBOXYLIC ACID Basic information

Product Name:
3,6-DICHLORO-BENZO[B]THIOPHENE-2-CARBOXYLIC ACID
Synonyms:
  • 3,6-dichloro-2-benzothiophenecarboxylic acid
  • 3,6-dichlorobenzothiophene-2-carboxylic acid
  • BT2
  • JR-6478, 3,6-Dichlorobenzo[b]thiophene-2-carboxylic acid, 97%
  • Benzo[b]thiophene-2-carboxylic acid, 3,6-dichloro-
  • 3,6-Dichloro-1-benzothiophene-2-carboxylicaci
  • 3,6-DICHLORO-BENZO[B]THIOPHENE-2-CARBOXY
  • Bcl-2 Family,BT2,Inhibitor,BT-2,inhibit,BT 2
CAS:
34576-94-8
MF:
C9H4Cl2O2S
MW:
247.1
Mol File:
34576-94-8.mol
More
Less

3,6-DICHLORO-BENZO[B]THIOPHENE-2-CARBOXYLIC ACID Chemical Properties

Boiling point:
426.4±40.0 °C(Predicted)
Density 
1.653±0.06 g/cm3(Predicted)
storage temp. 
2-8°C
solubility 
Soluble in DMSO (up to at least 20 mg/ml)
pka
2.09±0.30(Predicted)
form 
solid
color 
Off-white
Stability:
Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 3 months.
More
Less

3,6-DICHLORO-BENZO[B]THIOPHENE-2-CARBOXYLIC ACID Usage And Synthesis

Description

3,6-dichloro-benzo[b]thiophene-2-Carboxylic acid is an inhibitor of myeloid cell leukemia 1 (Mcl-1) with a Ki value of 59 μM for binding of FITC-Mcl-1-BH2 peptide binding to Mcl-1. It has been used as a building block in the synthesis of inhibitors of Mcl-1, the toll-like receptor 3/double-stranded RNA (TLR3/dsRNA) complex, and D-amino acid oxidase (DAO).

Uses

BT2 is a BCKDC kinase (BDK) inhibitor with an IC50 of 3.19 μM. BT2 binding to BDK triggers helix movements in the N-terminal domain, resulting in the dissociation of BDK from the branched-chain α-ketoacid dehydrogenase complex (BCKDC)[1]. BT2 (compound 4) is also a potent and selective Mcl-1 inhibitor with a Ki value of 59 μM[2].

in vivo

BT2 (20 mg/kg/day; intraperitoneal injection; daily; for 7 days; C57BL/6J male mice) treatment robustly enhances BCKDC activity in the heart (12.3-fold) compared with the vehicle-treated animals. Less activation is obtained in muscle and kidney at 3.6- and 3.8-fold, respectively. The -fold activation of BCKDC activity in the above tissues correlates with decreased phosphorylation in heart, muscle, and kidney after the long term BT2 treatment. BT2 treatment reduces the protein levels of BDK in kidneys and heart[1].

Animal Model:C57BL/6J male mice (8-10-week-old)[1]
Dosage:20 mg/kg/day
Administration:Intraperitoneal injection; daily; for 1 week
Result:BCKDC activity was robustly (12.3-fold) enhanced in the heart compared with the vehicle-treated animals. Less activation was obtained in muscle and kidney at 3.6- and 3.8-fold, respectively. The protein levels of BDK in kidneys and heart were reduced to averages of 39 and 24%, respectively.

IC 50

BDK: 3.19 μM (IC50); Mcl-1: 59 μM (Ki)

References

[1] SHIH-CHIA TSO. Benzothiophene carboxylate derivatives as novel allosteric inhibitors of branched-chain α-ketoacid dehydrogenase kinase.[J]. The Journal of Biological Chemistry, 2014, 289 30: 20583-20593. DOI:10.1074/jbc.m114.569251
[2] ANDERS FRIBERG. Discovery of Potent Myeloid Cell Leukemia 1 (Mcl-1) Inhibitors Using Fragment-Based Methods and Structure-Based Design[J]. Journal of Medicinal Chemistry, 2012, 56 1: 15-30. DOI:10.1021/jm301448p

3,6-DICHLORO-BENZO[B]THIOPHENE-2-CARBOXYLIC ACIDSupplier

BOC Sciences
Tel
1-631-485-4226; 16314854226
Email
info@bocsci.com
SynAsst Chemical.
Tel
021-60343070
Bide Pharmatech Ltd.
Tel
400-164-7117 13681763483
Email
product02@bidepharm.com
Suzhou Laing Biological Technology Co., LTD
Tel
0512-62968256 18550502935
Email
export@laingbiotec.com
ShangHai AmK Pharmaceutical Technology Co., Ltd.
Tel
微信 17321281695 18019252918
Email
sale@amkchem.com
More
Less

3,6-DICHLORO-BENZO[B]THIOPHENE-2-CARBOXYLIC ACID(34576-94-8)Related Product Information